Clinical Trials Directory

Trials / Completed

CompletedNCT02911935

Azithromycin to Prevent Wheezing Following Severe RSV Bronchiolitis-II

Status
Completed
Phase
Phase 2 / Phase 3
Study type
Interventional
Enrollment
200 (actual)
Sponsor
Washington University School of Medicine · Academic / Other
Sex
All
Age
1 Month – 18 Months
Healthy volunteers
Not accepted

Summary

The main objective of the APW-RSV II clinical trial is to evaluate if the addition of azithromycin to routine bronchiolitis care, among infants hospitalized with RSV bronchiolitis, reduces the occurrence of recurrent wheeze during the preschool years.

Detailed description

The APW-RSV II clinical trial is a double blind, placebo-controlled, parallel-group, randomized trial, including otherwise healthy 188 participants, ages 1-18 months, who are hospitalized due to RSV bronchiolitis. The study includes active treatment phase with azithromycin or placebo for 2 weeks, and an observational phase for up to 48 months. The main objective of the APW-RSV II clinical trial is to evaluate if the addition of azithromycin to routine bronchiolitis care, among infants hospitalized with RSV bronchiolitis, reduces the occurrence of recurrent wheeze (RW) during the preschool years. Study participants will be enrolled during 3 consecutive RSV seasons beginning in Fall 2016. Study participants will be randomized to receive PO azithromycin 10 mg/kg/day for 7 days followed by 5mg/kg/day for additional 7 days, or matched placebo. The primary clinical outcome is the time to the occurrence of a third episode of wheezing. The duration of follow up is 18-48 months, which is determined based on the year in which the participants is recruited: first year recruits will be followed for up to 48 months, while the 3rd year recruits will be followed for at least 18 months.

Conditions

Interventions

TypeNameDescription
DRUGOral azithromycinOral azithromycin 10mg/kg/day for 7 days; then oral azithromycin 5mg/kg/day for 7 additional days
DRUGPlaceboPlacebo suspension

Timeline

Start date
2016-11-01
Primary completion
2021-04-01
Completion
2021-04-01
First posted
2016-09-22
Last updated
2022-06-07
Results posted
2022-06-07

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02911935. Inclusion in this directory is not an endorsement.